Rapt Therapeutics (RAPT) Competitors $12.65 -1.29 (-9.25%) Closing price 04:00 PM EasternExtended Trading$13.10 +0.45 (+3.52%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RAPT vs. PGEN, ARVN, TBPH, SAGE, ORGO, TSHA, ABVX, BCYC, BCAX, and ORKAShould you be buying Rapt Therapeutics stock or one of its competitors? The main competitors of Rapt Therapeutics include Precigen (PGEN), Arvinas (ARVN), Theravance Biopharma (TBPH), Sage Therapeutics (SAGE), Organogenesis (ORGO), Taysha Gene Therapies (TSHA), Abivax (ABVX), Bicycle Therapeutics (BCYC), Bicara Therapeutics (BCAX), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry. Rapt Therapeutics vs. Its Competitors Precigen Arvinas Theravance Biopharma Sage Therapeutics Organogenesis Taysha Gene Therapies Abivax Bicycle Therapeutics Bicara Therapeutics Oruka Therapeutics Rapt Therapeutics (NASDAQ:RAPT) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment. Does the media refer more to RAPT or PGEN? In the previous week, Rapt Therapeutics had 4 more articles in the media than Precigen. MarketBeat recorded 7 mentions for Rapt Therapeutics and 3 mentions for Precigen. Precigen's average media sentiment score of 0.91 beat Rapt Therapeutics' score of 0.34 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapt Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, RAPT or PGEN? Rapt Therapeutics has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Which has preferable valuation & earnings, RAPT or PGEN? Precigen has higher revenue and earnings than Rapt Therapeutics. Precigen is trading at a lower price-to-earnings ratio than Rapt Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapt Therapeutics$1.53M136.75-$129.87M-$19.20-0.66Precigen$3.92M120.48-$126.24M-$0.56-2.86 Do analysts prefer RAPT or PGEN? Rapt Therapeutics presently has a consensus target price of $21.67, suggesting a potential upside of 71.28%. Precigen has a consensus target price of $6.00, suggesting a potential upside of 275.00%. Given Precigen's stronger consensus rating and higher probable upside, analysts plainly believe Precigen is more favorable than Rapt Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapt Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43Precigen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is RAPT or PGEN more profitable? Rapt Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -3,728.87%. Rapt Therapeutics' return on equity of -81.47% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Rapt TherapeuticsN/A -81.47% -70.24% Precigen -3,728.87%-279.20%-79.74% Do institutionals & insiders hold more shares of RAPT or PGEN? 99.1% of Rapt Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 2.4% of Rapt Therapeutics shares are owned by insiders. Comparatively, 47.1% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryPrecigen beats Rapt Therapeutics on 9 of the 16 factors compared between the two stocks. Get Rapt Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPT vs. The Competition Export to ExcelMetricRapt TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$230.51M$3.06B$5.67B$9.49BDividend YieldN/A2.44%4.05%4.00%P/E RatioN/A20.8627.9419.95Price / Sales136.75246.06396.5882.68Price / CashN/A41.9636.1958.45Price / Book1.108.308.635.82Net Income-$129.87M-$55.19M$3.24B$258.42M7 Day Performance23.66%5.07%3.22%1.94%1 Month Performance53.89%17.61%10.72%12.02%1 Year Performance-49.96%7.03%34.94%20.80% Rapt Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPTRapt Therapeutics4.3365 of 5 stars$12.65-9.3%$21.67+71.3%-42.9%$230.51M$1.53M0.0080News CoverageAnalyst UpgradePGENPrecigen4.0452 of 5 stars$1.95+6.6%$6.00+207.7%+0.6%$575.60M$4.20M-3.48190News CoverageARVNArvinas3.7558 of 5 stars$7.87+1.0%$20.29+157.8%-73.8%$574.43M$263.40M-11.92420News CoverageUpcoming EarningsTBPHTheravance Biopharma1.7695 of 5 stars$11.47+1.5%$16.60+44.7%+12.1%$573.50M$64.38M-9.72110SAGESage Therapeutics3.3405 of 5 stars$9.15-1.3%$8.75-4.4%-33.0%$572.97M$41.24M-1.58690Upcoming EarningsORGOOrganogenesis4.2605 of 5 stars$4.49+4.4%$6.00+33.6%+57.1%$569.56M$482.04M-26.41950TSHATaysha Gene Therapies3.7589 of 5 stars$2.64flat$8.17+209.3%+17.5%$566.70M$8.33M-7.76180ABVXAbivax2.6866 of 5 stars$8.83+6.8%$31.00+251.1%+469.8%$560.44MN/A0.0061Trending NewsAnalyst ForecastHigh Trading VolumeBCYCBicycle Therapeutics3.7429 of 5 stars$8.08+1.0%$25.00+209.4%-63.3%$559.54M$35.28M-2.57240BCAXBicara Therapeutics2.0354 of 5 stars$10.18+4.8%$31.86+213.0%N/A$555.22MN/A0.0032ORKAOruka Therapeutics2.7729 of 5 stars$14.70+3.3%$40.38+174.7%N/A$550.37MN/A-3.26N/ANews CoverageUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies Precigen Competitors Arvinas Competitors Theravance Biopharma Competitors Sage Therapeutics Competitors Organogenesis Competitors Taysha Gene Therapies Competitors Abivax Competitors Bicycle Therapeutics Competitors Bicara Therapeutics Competitors Oruka Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPT) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
